Drugs that contain Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir
1. Viekira Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501238 | ABBVIE | Anti-infective agents and uses thereof |
Sep, 2028
(4 years from now) | |
| US8188104 | ABBVIE | Anti-infective agents and uses thereof |
May, 2029
(5 years from now) | |
| US8642538 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | |
| US8420596 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(6 years from now) | |
| US8691938 | ABBVIE | Anti-viral compounds |
Apr, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
| US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(4 months from now) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(4 months from now) | |
| US9139536 | ABBVIE | Anti-infective agents and uses thereof |
Nov, 2028
(4 years from now) | |
| US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9044480 | ABBVIE | Compositions and methods for treating HCV |
Apr, 2031
(6 years from now) | |
| US8686026 | ABBVIE | Solid compositions |
Jun, 2031
(7 years from now) | |
| US10201541 | ABBVIE | Compositions and methods for treating HCV |
May, 2032
(8 years from now) | |
| US10201584 | ABBVIE | Compositions and methods for treating HCV |
May, 2032
(8 years from now) | |
| US8466159 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8680106 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8685984 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8492386 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US10105365 | ABBVIE | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | |
| US9333204 | ABBVIE | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | |
| US9744170 | ABBVIE | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
NCE-1 date: 19 December, 2018
Market Authorisation Date: 22 July, 2016
Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using dasabuvir/ombitasvir/paritaprev...
Dosage: TABLET, EXTENDED RELEASE;ORAL
VIEKIRA XR family patents
